Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Yau, T. [1 ]
Meyer, T. [2 ]
Kelley, R. K. [3 ]
Mangeshkar, M. [4 ]
Cheng, A-L. [5 ]
El-Khoueiry, A. B. [6 ]
Abou-Alfa, G. K. [7 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Royal Free Hosp, Oncol, London, England
[3] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[4] Exelixis, Biostat, Alameda, CA USA
[5] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[7] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
    Kelley, R. K.
    Yau, T.
    Cheng, A. -L.
    Kaseb, A.
    Qin, S.
    Zhu, A. X.
    Chan, S.
    Sukeepaisarnjaroen, W.
    Breder, V.
    Verset, G.
    Gane, E.
    Borbath, I.
    Rangel, J. D. Gomez
    Merle, P.
    Benzaghou, F. M.
    Banerjee, K.
    Hazra, S.
    Fawcett, J.
    Rimassa, L.
    ANNALS OF ONCOLOGY, 2022, 33 (01) : 114 - 116
  • [42] Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
    Miksad, R.
    Cicin, I.
    Chen, Y.
    Klumpen, H.
    Kim, S.
    Lin, Z.
    Youkstetter, J.
    Sen, S.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 134 - 134
  • [43] Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
    Dollinger, Matthias M.
    Lautenschlaeger, Christine
    Lesske, Joachim
    Tannapfel, Andrea
    Wagner, Anna-Dorothea
    Schoppmeyer, Konrad
    Nehls, Oliver
    Welker, Martin-Walter
    Wiest, Reiner
    Fleig, Wolfgang E.
    BMC CANCER, 2010, 10
  • [44] Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
    Matthias M Dollinger
    Christine Lautenschlaeger
    Joachim Lesske
    Andrea Tannapfel
    Anna-Dorothea Wagner
    Konrad Schoppmeyer
    Oliver Nehls
    Martin-Walter Welker
    Reiner Wiest
    Wolfgang E Fleig
    BMC Cancer, 10
  • [45] Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study
    Li, D.
    Loriot, Y.
    Burgoyne, A.
    Cleary, J.
    Santoro, A.
    Lin, D.
    Aix, S. Ponce
    Garrido-Laguna, I.
    Sudhagoni, R.
    Lougheed, J.
    Andrianova, S.
    Paulson, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S241 - S241
  • [46] Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen L.
    Lim, Ho Yeong
    Baron, Ari D.
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas
    Lougheed, Julie C.
    Milwee, Steven
    El-Khoueiry, Anthony B.
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    ESMO OPEN, 2020, 5 (04) : 1 - 9
  • [47] PROGNOSTIC FACTORS IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB: A RETROSPECTIVE COMPARISON WITH PREVIOUSLY KNOWN PROGNOSTIC MODELS
    Baek, K. K.
    Kim, J.
    Kim, J. E.
    Park, S. H.
    Lee, J. Y.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Kang, W. K.
    ANNALS OF ONCOLOGY, 2010, 21 : 259 - 259
  • [48] IPILIMUMAB IMPROVES SURVIVAL IN PREVIOUSLY TREATED, ADVANCED MELANOMA PATIENTS WITH POOR PROGNOSTIC FACTORS: SUBGROUP ANALYSES FROM A PHASE III TRIAL
    Lebbe, C.
    McDermott, D. F.
    Robert, C.
    Lorigan, P.
    Ottensmeier, C. H.
    Wolchok, J.
    Garbe, C.
    Messina, M.
    Hoos, A.
    Weber, J. S.
    ANNALS OF ONCOLOGY, 2010, 21 : 401 - 401
  • [49] Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models
    Baek, Kyung Kee
    Kim, Jung-Hoon
    Uhm, Ji Eun
    Park, Se Hoon
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Kang, Won Ki
    Lim, Ho Yeong
    ONCOLOGY, 2011, 80 (3-4) : 167 - 174
  • [50] Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
    Abou-Alfa, Ghassan K.
    Puig, Oscar
    Daniele, Bruno
    Kudo, Masatoshi
    Merle, Philippe
    Park, Joong-Won
    Ross, Paul
    Peron, Jean-Marie
    Ebert, Oliver
    Chan, Stephen
    Poon, Tung Ping
    Colombo, Massimo
    Okusaka, Takuji
    Ryoo, Baek-Yeol
    Minguez, Beatriz
    Tanaka, Takayoshi
    Ohtomo, Toshihiko
    Ukrainskyj, Stacey
    Boisserie, Frederic
    Rutman, Olga
    Chen, Ya-Chi
    Xu, Chao
    Shochat, Eliezer
    Jukofsky, Lori
    Reis, Bernhard
    Chen, Gong
    Di Laurenzio, Laura
    Lee, Ray
    Yen, Chia-Jui
    JOURNAL OF HEPATOLOGY, 2016, 65 (02) : 289 - 295
12345